Business Wire

A2RL

28.4.2024 13:58:27 CEST | Business Wire | Press release

Share
TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit

TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire)

Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000 spectators at the circuit and captured the attention of over 600,000 online viewers in just 12 hours. Organized by ASPIRE, a subsidiary of Abu Dhabi’s Advanced Technology Research Council (ATRC), A2RL fuses extreme autonomous racing and AI to accelerate the global development of autonomous systems and technologies.

Following months of meticulous preparation spent refining driving AI algorithms in simulations, A2RL’s customized Dallara Super Formula SF23 cars tested the limits of human ingenuity and AI capability. Each team utilized an identical Super Formula race car - the fastest open-wheel race car in the world after Formula One- adapted for autonomous racing by the Technology Innovation Institute (TII), a sister company of ASPIRE.

Teams faced a complex task in coding. From understanding grip levels, managing tire temperatures, predicting opponent movements, performing successful overtakes, and operating the SF23 right at the limit of grip, the AI needed to perform all the things that racing drivers do intuitively. Additionally, with four autonomous cars racing on the track simultaneously, it marked a world-first attempt that added another layer of challenge.

In a last-lap shootout, the German outfit TUM snatched first place in a daring overtake when front-running Italian team UNIMORE slowed down and came to a stop on the track. The team was congratulated on the racetrack by H.H. Theyab bin Mohamed bin Zayed, who presented the Championship Trophy, along with H.E. Faisal Al Bannai, Secretary General, ATRC, and Strategic Research & Advanced Technology Affairs Advisor to the UAE President.

Simon Hoffmann, Team Principal, said: “This event has been nothing short of extraordinary, and the finale was our defining moment. We are absolutely thrilled with the outcome; it speaks volumes about our collective engineering prowess, coding expertise, and sheer determination. It's a testament to the incredible power of AI driving the evolution of autonomous mobility into the future!"

Spectators also enjoyed the riveting AI versus Human Race, where the Technology Innovation Institute (TII), pitted its autonomous car against renowned Formula One driver Daniil Kvyat. While Kvyat managed to hold his own and edge past his autonomous adversary by 10.38 secs, the spectacular 45-minute race highlighted just how close the autonomous race car performs against a human driver.

H.E. Al Bannai, said: “Through the Abu Dhabi Autonomous Racing League, we've sparked a race revolution. Showcasing fully autonomous racecars competing wheel-to-wheel, we've redefined the UAE's role in innovation and set a bold precedent for global mobility. This event isn't just a race; it's a transformative moment where technology, imagination, and ambition converge. A2RL serves as a beacon, inspiring the next generation through physical and virtual realities, while shaping a future where the impossible becomes achievable."

H.E. Dr. Sultan Al Jaber, Minister of Industry and Advanced Technology, and Group MD & CEO of ADNOC, as Title Sponsor, said: “Advances in artificial intelligence promise to transform every industry. The A2RL demonstrates the application of AI and as title sponsor, ADNOC is proud to help push the frontiers of science and innovation.”

Stephane Timpano, CEO of ASPIRE, said: “The launch of A2RL has reshaped the landscape of sports and technology, leaving a lasting impact for years to come. Moving forward, we're broadening our focus to include different vehicle types, while actively attracting top talent worldwide to showcase their mettle.”

On the sidelines of the main event, the A2RL STEM Challenge for high-school and undergrad students between the ages of 14 and 21 drew the participation of 18 local schools, in addition to an international entry from the Boys and Girls Club from Southeastern Michigan, to showcase their knowledge, skills, and innovation by racing 1:8 scale autonomous cars. The winner of the A2RL STEM Challenge was Heriot-Watt University.

A2RL pioneered the integration of mixed and virtual reality elements for the first time in autonomous racing. It gave each of the eight finalist teams a unique avatar persona and incorporated state-of-the-art Virtual Reality (VR) technology ahead of F1 implementation, igniting enthusiastic fan experience both online and offline. Fans at the event in Yas Marina Circuit got to enjoy insightful STEM workshops, intriguing VR challenges, Gran Turismo simulators, doodle cars, and a Raceum AI Museum, among other activities. The inaugural event concluded with a spectacular display of fireworks and drones, illuminating the iconic Yas Marina Circuit.

A2RL 2024 was successfully supported by ADNOC as Title Sponsor, and leading partners, including Du, DMT, AWS, and Mubadala, who played pivotal roles in shaping the event’s trajectory.

Details of the eight participating teams and other updates can be found at A2RL.io.

Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240428292385/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye